Evidence map›Paper›PMID 32565798›Full record

ArticleJournal of oncology2020

Nomogram for Predicting Recurrence-Free Survival in Chinese Women with Endometrial Cancer after Initial Therapy: External Validation.

Yuan Cheng, Yangyang Dong, Wenjuan Tian, Hua Zhang, Xiaoping Li, Zhiqi Wang, Boer Shan, Yulan Ren, Lihui Wei, Huaying Wang and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yuan ChengDepartment of Obstetrics and Gynecology, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng Dist., Beijing 100044, China.
Yangyang DongDepartment of Obstetrics and Gynecology, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng Dist., Beijing 100044, China.
Wenjuan TianDepartment of Gynecology, Fudan University Shanghai Cancer Center, No. 255, Dong'An Road, Shanghai 200032, China.
Hua ZhangResearch Center of Clinical Epidemiology, Peking University Third Hospital, Xueyuan Rd 38#, Haidian Dist., Beijing 100191, China.
Xiaoping LiDepartment of Obstetrics and Gynecology, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng Dist., Beijing 100044, China.
Zhiqi WangDepartment of Obstetrics and Gynecology, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng Dist., Beijing 100044, China.
Boer ShanDepartment of Gynecology, Fudan University Shanghai Cancer Center, No. 255, Dong'An Road, Shanghai 200032, China.
Yulan RenDepartment of Gynecology, Fudan University Shanghai Cancer Center, No. 255, Dong'An Road, Shanghai 200032, China.
Lihui WeiDepartment of Obstetrics and Gynecology, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng Dist., Beijing 100044, China.
Huaying WangDepartment of Gynecology, Fudan University Shanghai Cancer Center, No. 255, Dong'An Road, Shanghai 200032, China.ORCID https://orcid.org/0000-0002-3780-4497
Jianliu WangDepartment of Obstetrics and Gynecology, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng Dist., Beijing 100044, China.ORCID https://orcid.org/0000-0001-8932-317X
Peking University · CNFudan University Shanghai Cancer Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed at developing an available recurrence-free survival (RFS) model of endometrial cancer (EC) for accurate and individualized prognosis assessment. A training cohort of 520 women with EC who underwent initial surgical treatment and an external validation cohort of 445 eligible EC patients from 2006 to 2016 were analyzed retrospectively. Multivariable Cox proportional hazards regression models were used to develop nomograms for predicting recurrence. The concordance index (C-index) and the area under the receiver operating characteristic curve (AUC) were calculated to determine the discrimination of RFS prognostic scoring systems. Calibration plots were generated to examine the performance characteristics of the predictive nomograms. Regression analysis revealed that an advanced International Federation of Gynecology and Obstetrics (FIGO) stage, histological grade 3, primary tumor diameter ≥2 cm, and positive peritoneal cytology were independent prognostic factors for RFS in EC in the training set. The nomograms estimated RFS according to these four variables, with a C-index of 0.860, which was superior to that of FIGO stage (2009 criteria), at 0.809 (

Identifiers

PMID32565798
PMCPMC7275963
OpenAlexW3030156267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.